No connection

Search Results

CCEL vs MYO

CCEL
Cryo-Cell International, Inc.
BEARISH
Price
$3.67
Market Cap
$29.6M
Sector
Healthcare
AI Confidence
95%
MYO
Myomo, Inc.
BEARISH
Price
$0.79
Market Cap
$30.5M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
CCEL
--
MYO
--
Forward P/E
CCEL
183.5
MYO
-3.02
P/B Ratio
CCEL
-1.61
MYO
2.68
P/S Ratio
CCEL
0.95
MYO
0.75
EV/EBITDA
CCEL
31.86
MYO
-2.33

Profitability

Gross Margin
CCEL
63.53%
MYO
65.7%
Operating Margin
CCEL
9.96%
MYO
-24.43%
Profit Margin
CCEL
-8.52%
MYO
-38.05%
ROE
CCEL
--
MYO
-86.24%
ROA
CCEL
0.19%
MYO
-22.26%

Growth

Revenue Growth
CCEL
-3.6%
MYO
-5.9%
Earnings Growth
CCEL
-80.5%
MYO
--

Financial Health

Debt/Equity
CCEL
--
MYO
1.7
Current Ratio
CCEL
0.62
MYO
3.3
Quick Ratio
CCEL
0.55
MYO
2.69

Dividends

Dividend Yield
CCEL
16.35%
MYO
--
Payout Ratio
CCEL
3962.91%
MYO
0.0%

AI Verdict

CCEL BEARISH

CCEL exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price/Book ratio of -1.61, suggesting negative shareholder equity. The company's dividend is fundamentally unsustainable with a payout ratio of 3962.91%, indicating that dividends are being paid out of capital or debt rather than earnings. While gross margins remain strong, the combination of declining YoY revenue (-3.60%) and crashing earnings growth (-80.50%) creates a precarious outlook. Liquidity is a critical concern with a current ratio of 0.62, placing the firm at significant short-term financial risk.

Strengths
Strong gross margins at 63.53%
Positive operating margin of 9.96%
Low Price/Sales ratio of 0.95
Risks
Negative equity as indicated by Price/Book ratio of -1.61
Severe liquidity risk with a current ratio of 0.62 and quick ratio of 0.55
Unsustainable dividend payout ratio (3962.91%)
MYO BEARISH

MYO exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across nearly all health metrics. Despite a high gross margin of 65.7%, the company suffers from negative revenue growth (-5.90%) and a catastrophic year-over-year EPS decline of 800%. While analyst target prices ($4.32) suggest a massive upside, this is completely decoupled from the current financial reality of negative profitability and a bearish technical trend. The company is currently a high-risk micro-cap with deteriorating fundamentals.

Strengths
Strong Gross Margin (65.70%)
Healthy Current Ratio (3.30) suggesting short-term liquidity
Low Price-to-Sales ratio (0.75)
Risks
Critical Piotroski F-Score (1/9) indicating poor financial health
Negative Revenue Growth (-5.90% YoY)
Extreme negative ROE (-86.24%) and ROA (-22.26%)

Compare Another Pair

CCEL vs MYO: Head-to-Head Comparison

This page compares Cryo-Cell International, Inc. (CCEL) and Myomo, Inc. (MYO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile